品牌名称：

型号规格：

批准文号： 仅供科研使用

产品标签：

产品卖点：

销售渠道：医院

025-86978335

产品介绍：

【产品名称】

通用名称：功能性IGF结合蛋白3检测试剂盒（酶联免疫法）

英文名称：functional IGFBP-3 LIA

【预期用途】

用于测定生物活性和功能性 IGFBP-3。仅供科研使用。不用于临床诊断。

【包装规格】

96T/盒

【背景知识】

以前用于 IGFBP-3 定量的免疫测定使用 IGFBP-3 特异性抗体的结合来产生信号。由于该系统，它们无法区分完整的 IGFBP-3 分子及其片段（例如来自蛋白水解切割）。在某些情况下，测量值因此过高，因为完整的 IGFBP-3 分子可能会产生几个片段，因此无法区分 IGFBP-3 值增加和片段化率高。

仅识别 IGFBP-3 的初始 IGFB 结合位点的单克隆抗体基本上是间接的和不精确的，因为蛋白酶可以产生范围广泛的片段，其中一些由于缺乏 IGF 结合而可以被抗体识别。然而，-3 LIA 能够测量实际功能性和有效生物活性的 IGFBP-3。这里，功能性被定义为与最重要的天然配体 IGF-I 结合的能力。

新的测试原理（专利申请中的 DE19719001）使用固定的抗 lGFBP-3 抗体和生物素化的 IGF-i 作为配体。与微量滴定板偶联的 IGFBP-3 抗体与样品中的 IGFBP-3 结合，并且只有当 lIGFBP-3 也同时结合生物素化的 IGF-1 时，才会在测试中产生信号。因此，只有功能性 IGFBP-3 被量化！

获得专利的测试格式确保了简单和可靠的性能，与传统的市售 ELISA 试剂盒一样。时间和劳动密集型的生化分析（例如凝胶色谱或蛋白质印迹等）只允许估计浓度，已成为多余。

胰岛素样生长因子 (IGF)-I 和 -II 与血流中的特异性结合蛋白 (IGFBP) 结合。到目前为止，已根据其氨基酸序列鉴定出七种不同的结合蛋白，并将其分类为 IGFBP-1、IGFBP-2、.IGFBP-7 (1/2)。在血液中，IGFBP-3 占主导地位。与其他结合蛋白相比，除了 lGF-I 或 -II (3-5) 之外，lGFBP-3 还具有结合酸不稳定亚基 (ALS) 的独特特性。IGFBP-3 几乎完全以这种高分子燕鸥复合物，只能在血液中找到少量的游离 IGFBP-3 (6,7)。

开发出也可识别三元复合物中 IGFBP-3 的特异性免疫测定法为该蛋白的调节提供了新的见解 (6-9)。因此，IGFBP-3 被证明是诊断生长障碍的有用参数（见下文；7,8）。

由此可见，GH缺乏的患者IGFBP-3水平低于正常水平，而GH分泌正常的矮身高儿童的IGFBP-3水平也大多在正常范围内（图1）。 IGFBP-3 水平 一次测量就足以准确诊断 GH 缺乏症 (7,18)。在身材矮小的儿童中，IGFBP-3 水平在持续 GH 治疗期间稳步上升至正常范围，并在持续治疗期间保持不变（图 2）。因此，测量血清中的 IGFBP-3 也可用于监测 GH 疗法 (19)。在其他明显身材矮小但 GH 分泌异常的患者中，例如： B、Tumer综合征或Silver-Russell综合征，IGFBP-3血清值也正常（8）。

在体重正常的儿童和青少年或Sotos综合征患者中，IGFBP-3值正常或略有升高。相比之下，巨人症儿童或肢端肥大症成人的数值大大增加（图3）（6,15），并在成功治疗后恢复正常。因此，IGFBP-3 测量也是诊断 GH 过多和监测治疗成功的有用参数。早熟儿童的 IGFBP-3 水平显着升高，而早产儿的 IGFBP-3 水平处于正常范围的上限（15） .

除了生长激素，还有其他影响IGFBP-3水平的因素：年龄和性发育、饮食、甲状腺功能减退、糖尿病、肝肾功能。l)、甲状腺功能减退、糖尿病和肝病(6-8) . 但是，在存在慢性肾功能不全的情况下，这些值会增加（6,10,11）。 24 小时测量显示没有昼夜波动(12,13)。对于临床目的，生长激素是一个重要的调节因素。

IGFBP-3 单次测量与自发总 GH 分泌的对数正相关 (8,14)。在 wHi 缺乏的患者中，IGFBP-3 值也会降低。在添加 GH 数天后，IGFBP-3 水平缓慢上升至正常范围)(7,8)。全天对GH浓度变化和恒定水平的缓慢反应每日 GH 给药的过程 (13) 表明 IGFBP-3 反映了几天内的 GH 分泌状态。

参考文献：

1. Ballard J,Baxter R, Binoux M.Clemmons D, dro S, Hall K, Hintz R, Rechler M, RutanenE, Schwander J(1989) On the nomenclature of the IGF binding proteins.Acta Endocrinol (Copenh)121:751-752

2. wilson EM,Oh Y，Rosenfeld RG(1997)Generation and characterization of an lGFBP-7 antibody:ldentification of 31 kD·IGFBP-7 in human biological fuids and Hs578T human breast cancer conditionedmedia.J Clin Endocrinol metab vol82,4:1301-1303

3. Baxter RC (1988)Characterization of the acid-labile subunit of the growth hormone-dependent insulin-likegrowth factor binding protein complex.J Clin Endocrinol metab 67:265-272

4. Baxter RC,Martin JL(1989) Structure of the Mr 140,000 growth hormone dependent insulin-like growthfactor binding protein complex: determinati-on by reconstitution and affinity-labeling. Proc Natl Acad Sci USA86:6898-6902

5. Holman SR, Baxter RC (1996)Insulin-like growth factor-binding protein-3: factors affecting binary andternary complex formation.Growth Regulation 6: 42-47.

6. Baxter RC,Martin J(1986): Radioimmunassay of growth hormone-dependent insulin-like growth factorbinding protein in human plasma.J Clin Invest 78:1504-1512

7. Blum WF,Ranke MB, Kietzmann K ,Gauggel E, Zeissel HJ, Bierich JR (1990) A specific radioimmunoassayfor the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GHdeficiency.J Clin Endocrinoi metab 70:1292-1298

8. Blum WF， Ranke MB (1990) Use of insulin-like growth factor binding protein 3 for the evaluation of growthdisorders.Horm Res 34 (Suppl):31-37

9. Blum WF (1993) Insulin-like growth factor-binding protein 3:Entwicklung eines Radioimmunoassays undUntersuchungen zur klinischen Bedeutung. Habilitationsschrift, Tübingen.

10. Lee PDK, Hintz RL，Sperry JB，Baxter RC, Powell DR (1989)IGF-binding proteins in growth-retardedchildren with chronic renal failure.Pediatr Res 26:308-315

11. Blum WF, Ranke MB, Kietzmann K,T6nshoff B, Mehls 0 (1989)Excess of-lGF-binding proteins in chronicrenal failure: evidence for relative GH resistence and inhibition of somatomedin activity. In: dro SLS, HintzRL(eds) Insulin-like Growth Factor Binding Proteins. Excerpta Medica, Amsterdam, pp 93-101

12. Baxter RC,Cowell CT (1987) Diurnal thythm of growth hormone-indepen-dent binding protein for insulin-like growth factors in human plasma.JClin Endocrinol metab 65:432-440

13. Jorgensen JOL,Blum WF,Moller N,Ranke MB,Christiansen JS (1990)Circadian patterns of serum insulin-like growth factor (IGF)-ll and IGF-binding protein 3 in growth hormone deficient patients and age-and sex-matched normal subjects.Acta Endocrinol (Copenh.)123:257-262

14. Blum WF, Albertsson-Wiland K, Rosberg S, Jorgensen JOL, Ranke MB (1990) Insulin-like growth factorbinding protein 3(IGFBP-3) reflects spontaneous growth hormone(GH) secretion. Horm Res 33 (Suppl 3)3(Abstract)

15. Blum WF, Ranke MB(1990) Insulin-like growth factor-binding proteins (IGFBPs) with special reference toIGFBP-3.Acta Paediatr Scand (Suppl) 367:55-62

16. Gudice LC，Farrell EM,Pham H, Lamson G，Rosenfeld RG (1990)Insulin-like growth factor binding

proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associatedserum protease activity.J ClinEndocrinol metab 71:806 816

17.Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M,Binoux M(1990) Evidence of enzymaticdegradation of insulin-like growth factor-binding proteins in the 150k complex during pregnancy.J ClinEndocrinol metab 71:797-805

18.Ranke MB, Schweizer R，ElImlinger Mw，Weber K,Binder G,Schwarze CP, Wollmann HA (20oo)Significance of Basal IGF-J，IGFBP-3 and IGFBP-2 Measrurements in the diagnostics of short stature inchildren.Horm Res 2000;54:60-68

19. Ranke MB,Schweizer R,Eimlinger Mw，Weber K,Binder G,Schwarze CP,Wollmann HA (2001)Relevance of IGF-l,IGFBP-3, and lGFBP-2 Measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents.Horm Res 2001;55:115-124

20. Binoux M, L.C. Mohseni-Zadeh S. Biological Actions of Proteolytic Fragments of the IGF Binding Proteins.in The IGF System (ed.Rosenfeld R, R.C.)(Humana Press lnc,Totowa NJ,1999).

21. Maile LA, C.A.,Holly JMP.IGF Binding Protein Prtealysis in Various Clinical States. in The IGF System (ed.Rosenfeld R,R.C.)633-649 (Humana Press Inc,Totowa,NJ,1999).

22. Fielder PJ,G.-A.J.,Rosenbloom AL, Carisson L, Hintz RL, Rosenfeld RG.expression of serum insulin-like growth factors，insulin-like growth factor binding proteins,and the growth hormone binidng protein inheterozygote relatives of Ecuadorian growth hormone receptor deficient patients.J Clin Endocrinol metab74,743-750 (1992).

23. Cotteil AM,H.J., Taylor AM, Davies SC, Coulson vJ,Preece MA, Wass JAH,Savage MO. The insulin-like growth factor(IGF-)binding proteins and IGF bioactivity in Laron-type dwarfism.J Clin Endocrinol metab 74,56-63 (1992).

24. Davies DC, wW.J., Ross RJM, Cotterill AM,Buchanan CR, Coulson VJ, Holl JMP.The induction of a specific protease for insulin-like growth facotr binding protein-3 in the circulation during severe illness.J Endocrinol130,469-473 (1991).

25. Cwyfan Hughes sC,C.A，Molloy AR. Cassel TMB,Braude N, Hinds CH,Wass JAH.The induction ofspecific proteases for insulin-like growth factor binding proteins following major heart surgery. J Endocrinol135,135-145 (1992).

26. Timmins AC,C.A, Hughes scC, Holly JMP, Ross RJM, Blum w, Hinds CJ.Critical illness is associated with low circulting concentrations of insulin-like growth facor I and growth factor ll, alterations in insulin-likegrowth facor binding -proteins and induction of an insulin -like growth factor binding-protien-3 proatease-.CritCare Med 24,1460-1466 (1996).

27. Bang,P. Brismar K, Rosenfeld RG,Hall K.Fasting affects serum insulin-like growth factors (IGFs) and lGFbinding proteins differently in patients with non-insulin dependent diabetes versus healthy non-obese andobese subjects.J Clin Endocrinol metab 78,960-967 (1994).

28. Lang CH, F., Frost RA, Gelato MC， Sakurai Y, Herndon DN, WOlfe RR.Regulation of the insulin-likegrowth factor system by insulin burn patients.J Clin Endocrinol metab 81,2474-2480 (1996).

29. Frost VJ,H.S.,Lonning PE, van der Stappen J, HOlly JMP. Effects of treatment with megesterol acetate,aminoglutethimide or formestane on insulin.like growth factor (IGF)l an ll and lGF-binding proteins (IGFBPs)and IGFBP-3 protease status in patients with advanced breast cancer.J Clin Endocrinol metab 81,2216-2221 (1996).

30. Renehan AG, K.K., Diamandi A, ODwyer ST, Shalet SM.Quantification of serum IGFBP-3 proteolysis inpatients with colorectal cancer.Growth Horm IGF Res 13,217(2003).

31. Muller HL，O.Y.，Gargosky SE, Lehrnbecker T,Hintz RL,Rosenfeld RG. Concentrations of insulin-likegrowth factor(IGF) binding protien- 3(IGFBP-3), iGF and IGFBP-3 protease activity in cerebrospinal fluid ofchildren with leukemia, central nervous system tumor or meningitis.J Clin Endocrinol metab 77,113-1119(1993).

32. Fernihough JK,B.M.,Cwyfan-Hughes S, Holly JMP. Local disruption of the insulin-like growth factor system in the arthritic joint. Arthtis Rheum 39,1556-1565(Local disruption of the insulin-like growth factor system inthe arthitic joint.).

33. Lassarre C,M. Binoux.Measurement of intact lnsulin-Like Growth Factor-Binding Protein-3 in humanplasma using a ligand immunofunctional assay.J Clin Endocrinol metab 86,1260-1266 (2001)

34. Lassarre C, F. Duron,M. Binoux. Use of the Ligand lmmunofunctional Assay for human Insulin-like growthfactor (IGF) binding protein-3(IGFBP-3) to analyze lGFBP-3 proteolysis and IGF-l bioavailability in Healthyadults, GH-deficient and acromegalic patients, and diabetics.J Clin Endocrinol metab 86,1942-1952(2001)

35. Langkamp M.Weber K., Kirschner M., Pridzun L.,Ranke M.B.Validation of Fuctional insulin-Like Growth Factor Binding Protein-3 measurement by a Ligand lmmunoassay.Clin Lab.11+12/2010,56;535-542

• 功能位手托